Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

Rani Therapeutics has announced positive initial Phase 1a data for RT-114, an orally administered RaniPill® Capsule delivering PG-102, a GLP-1/GLP-2 dual agonist for obesity treatment.

In the study, oral RT-114 achieved systemic exposure greater than 150% relative to a matched 12 mg subcutaneous dose of PG-102, with no serious adverse events reported and no adverse events attributed to the RaniPill® Capsule itself.

The Phase 1a study is being expanded with an additional cohort to further define the oral-to-subcutaneous pharmacokinetic relationship, ahead of a planned Phase 1b repeat-dose study in patients with obesity expected to begin in 2026, with data anticipated in 2027.